Skip to main content

Susvimo FDA Approval History

Last updated by Judith Stewart, BPharm on Feb 5, 2025.

FDA Approved: Yes (First approved October 25, 2021)
Brand name: Susvimo
Generic name: ranibizumab
Dosage form: Injection for Intravitreal Use via Ocular Implant
Company: Genentech, Inc.
Treatment for: Macular Degeneration, Diabetic Macular Edema

Susvimo (ranibizumab) is a vascular endothelial growth factor (VEGF) inhibitor used for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular edema.

Development timeline for Susvimo

DateArticle
Feb  4, 2025Approval FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Treatment of Diabetic Macular Edema
Jul  8, 2024Genentech to Reintroduce Susvimo for People With Wet Age-Related Macular Degeneration (AMD)
Oct 22, 2021Approval FDA Approves Susvimo (ranibizumab) for the Treatment of Wet Age-Related Macular Degeneration (AMD)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.